Equity Overview
Price & Market Data
Price: $101.8
Daily Change: -$0.99 / 0.97%
Daily Range: $100.2 - $102.8
Market Cap: $19,685,756,928
Daily Volume: 1,694,596
Performance Metrics
1 Week: 4.62%
1 Month: -13.36%
3 Months: 44.28%
6 Months: 181.6%
1 Year: 141.0%
YTD: 27.85%
Company Details
Employees: 534
Sector: Health technology
Industry: Pharmaceuticals: other
Country:
Details
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.